Zhong Guo Jing Ji Wang·2026-03-02 04:18Group 1 - The core viewpoint of the announcement is that Fosun International plans to repurchase shares worth up to HKD 1 billion due to the belief that the current stock price does not reflect the company's long-term value [1] - The repurchase plan is seen as a demonstration of Fosun's confidence in its future development, particularly in light of recent commercialization of innovations and deepening global operations [1][2] - Analysts note that Fosun's core business segments, including biomedicine, cultural tourism, and insurance, have shown strong momentum since the beginning of 2026 [2] Group 2 - In the biomedicine sector, Fosun's innovative drug platform has made significant strides, including a deal with Eisai Co., Ltd. for a potential total of over USD 300 million in Japan, the fourth largest pharmaceutical market globally [2] - The company has also signed a global exclusive licensing agreement with Pfizer, potentially worth over USD 2 billion, and a strategic cooperation with Clavis Bio that could yield up to USD 7.25 billion in payments [2] - In the cultural tourism sector, Fosun's various product lines have performed well, with significant increases in visitor numbers and revenue during the Spring Festival period [2] Group 3 - In the insurance sector, Fosun's two domestic insurance companies reported substantial growth in premium income and net profit for 2025, with Fosun United Health Insurance achieving a revenue of HKD 7.84 billion, a 50% increase year-on-year [3] - Fosun's life insurance subsidiary, Fosun Baodexin, reported an insurance business income of HKD 12.598 billion, a 36.17% increase, and a net profit of HKD 647 million, reflecting a significant growth of over 450% year-on-year [3] - The robust growth in core businesses is considered a key catalyst for the share repurchase, as the company aims to improve its asset structure and market valuation [3][4]